11-deoxycortisol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 11-deoxycortisol
• 英文别名: 11-Deoxycortisol;cortexolone;Reichstein's substance S；(10R,13S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one
• 化学式: C₂₁H₃₀O₄
• 分子量: 346.467
• InChiKey: WHBHBVVOGNECLV-RCSFYLKVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  11-deoxycortisol 生成
  参考文献：
  名称：

  合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法

  摘要：

  本申请涉及一种合成21‑羟基‑17‑(1‑氧代丙氧基)孕甾‑4‑烯‑3,20‑二酮的方法，所述方法使用11‑脱氧皮醇为原料，通过化学合成保护基手段，选择性的将11‑脱氧皮醇的17α位的仲羟基酯化，同时保留11‑脱氧皮醇21位伯羟基予以保留不发生酯化，得到21‑羟基‑17‑(1‑氧代丙氧基)孕甾‑4‑烯‑3,20‑二酮。本申请方法为“一釜反应”中间产物无需分离纯化，更适合大批量工业制备，具有反应条件温和收率高、后处理简单等优点。

  公开号：

  CN112028956A

文献信息

• SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES
  申请人：Hartmann Rolf

  公开号：US20140155407A1

  公开（公告）日：2014-06-05

  The present invention relates to compounds which selectively inhibit CYP11B1. Preferably, the compounds of the present invention do not substantially inhibit CYP11B2. Moreover, the compounds of the present invention do not substantially inhibit CYP17 and/or CYP19, either. Amongst other applications of the compounds of the present invention, they can be used for the treatment of Cushing's syndrome or metabolic disease.

  本发明涉及一种选择性抑制CYP11B1的化合物。优选地，本发明的化合物不会显著抑制CYP11B2。此外，本发明的化合物也不会显著抑制CYP17和/或CYP19。在本发明化合物的其他应用中，它们可用于治疗库欣综合征或代谢疾病。
• [EN] 17A,21-DIESTERS OF CORTEXOLONE FOR USE IN THE TREATMENT OF TUMORS<br/>[FR] 17A,21-DIESTERS DE CORTELOXONE POUR UNE UTILISATION DANS LE TRAITEMENT DE TUMEURS
  申请人：COSMO TECHNOLOGIES LTD

  公开号：WO2016055533A1

  公开（公告）日：2016-04-14

  The present invention provides certain cortexolone derivatives of formula (I) and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.

  本发明提供了式（I）的某些皮质醇衍生物，用作抗肿瘤活性成分，用于治疗癌前病变、异型增生、上皮转化和肿瘤疾病，包括恶性肿瘤和转移。本发明的另一个方面涉及以式（I）的皮质醇衍生物为活性成分和至少一种生理上可接受的辅料的药物组成物，并将该药物组成物用作抗肿瘤药物。
• 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
  申请人：Cosmo Technologies Ltd.

  公开号：EP3006453A1

  公开（公告）日：2016-04-13

  The present invention provides certain cortexolone derivatives of formula (I) and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.

  本发明提供了某些式(I)的可的松衍生物 及其作为抗肿瘤活性成分用于癌前病变、发育不良、变性和肿瘤疾病（包括恶性肿瘤和转移）的治疗或辅助治疗、新辅助治疗或姑息治疗。 本发明的另一方面涉及包含作为活性成分的式(I)可的松衍生物和至少一种生理上可接受的赋形剂的药物组合物，以及所述药物组合物作为抗肿瘤药物产品的用途。
• CORTEXOLONE 17ALPHA-VALERATE FOR USE IN THE TREATMENT OF TUMOURS
  申请人：Cosmo Technologies Ltd

  公开号：EP3456330A1

  公开（公告）日：2019-03-20

  The present invention provides cortexolone 17.alpha.-valerate for use in therapy, in particular for use as an antitumor active ingredient for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis as well as for use as an glucocorticoid modulator (in particular an antagonist). Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone 17.alpha.-valerate as active ingredient and at least one physiologically acceptable excipient for these same therpeutic uses.

  本发明提供了用于治疗的可的松17.α.-戊酸酯，特别是作为抗肿瘤活性成分，用于癌前病变、发育不良、变性和肿瘤疾病（包括恶性肿瘤和转移）的治愈性或辅助性、新辅助性或姑息性治疗，以及作为糖皮质激素调节剂（特别是拮抗剂）。 本发明的另一方面涉及药物组合物，该组合物包含作为活性成分的可的松17.α.-戊酸酯和至少一种生理上可接受的赋形剂，用于这些相同的治疗用途。
• PROCESS FOR THE PREPARATION OF CORTEXOLONE 17 A-PROPIONATE AND NEW HYDRATED CRYSTALLINE FORM THEREOF
  申请人：Farmabios S.p.A.

  公开号：EP4071160A1

  公开（公告）日：2022-10-12

  The present invention is directed to a process for the preparation of cortexolone 17α-propionate, comprising a hydrolysis reaction of an ortho-ester of formula (III) in which R is a hydrogen atom or a methyl group, in the presence of a dilute solution of acetic acid. The present invention is also directed to a hydrated crystalline form of cortexolone 17a-propionate obtained by such process.

  本发明涉及一种制备可的松 17α 丙酸酯的工艺，包括式 (III) 原酯的水解反应 其中 R 是氢原子或甲基、 在稀醋酸溶液存在下进行水解反应。 本发明还涉及通过这种工艺获得的可的松 17a 丙酸酯的水合结晶形式。